Clinical Trials Logo

Clinical Trial Summary

The Pforzheim Tricuspid Valve Registry study is designed to confirm the safety and performance of the TriClip™ device in a contemporary real-world setting in critically ill patients. The observational trial is a prospective, single arm, open-label, single-center, post market registry.


Clinical Trial Description

Significant tricuspid regurgitation is a common finding in elderly patients, with an incidence of 5.6% after the age of 70 years, according to the Framingham Heart Study. TR is an independent predictor for adverse prognosis and has limited treatment options. Tricuspid valve (TV) intervention is indicated when symptomatic TR-related right heart failure (RHF) is present. However, the surgical risk is usually deemed to be too high due to the presence of advanced age, pulmonary hypertension, right ventricular (RV) impairment, major organ failure and other co-morbidities. Moreover, isolated tricuspid valve surgery has an in-hospital mortality of approx. 8,7%, according to recent data. High TR prevalence, coupled with low incidence of isolated TV surgery, has created a considerable population in need of alternative, percutaneous therapies to improve outcomes. Recently, a variety of interventional procedures and devices have been developed which simulate different surgical approaches like suture or ring annuloplasty, coaptation enhancement, neochordae repair, or even valve replacement. Among them, coaptation devices attempt to correct leaflet malcoaptation by using the edge-to-edge clip technique, similar to treatment of functional mitral regurgitation. To date, most TTVR interventions have been performed off-label with the MitraClip device. Last year, the first TR dedicated device (TriClipTM, Abbott Medical) has been approved (CE mark), after showing good feasibility, safety and effectiveness, and meanwhile sustained and marked clinical benefit with low mortality after 12 months. Although most TTVR studies have enrolled high-risk cohorts, criteria for patient selection and timing of intervention have yet to be defined. Based on scientific surgical data, it seems reasonable to expect poorer outcomes in patients with several comorbidities, advanced cardiac remodeling and RHF-related major organ dysfunction e.g., renal and hepatic function impairment. Whether or not this assumption can be extrapolated to TTVR needs to be investigated. In this registry, the investigators aim to evaluate if percutaneous therapy with the TriClip system is safe and effective in patients at high and prohibitive risk and wether or not procedural success is the main determinant of short-, mid- and long-term outcomes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05179616
Study type Observational [Patient Registry]
Source Helios Klinikum Pforzheim
Contact Ilka Ott, MD, PhD
Phone +4972319692955
Email [email protected]
Status Recruiting
Phase
Start date November 30, 2020
Completion date November 30, 2026

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05064514 - Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease N/A
Completed NCT03144024 - Comparison of Rigid Annuloplasty Ring With a Band in the Correction of Secondary Tricuspid Insufficiency N/A
Recruiting NCT04665583 - Prehab Prior to Undergoing Tricuspid Intervention
Not yet recruiting NCT04100720 - Early Feasibility Study of the Cardiovalve System for Tricuspid Regurgitation N/A
Completed NCT02981953 - TRI-REPAIR: TrIcuspid Regurgitation RePAIr With CaRdioband Transcatheter System N/A
Recruiting NCT04433065 - TTVR Early Feasibility Study N/A
Recruiting NCT04653428 - German Registry for Transcatheter Tricuspid Valve Interventions
Not yet recruiting NCT05006443 - Staging Classification of Severe Tricuspid Regurgitation Using Novel Cardiac Imaging Techniques N/A
Not yet recruiting NCT04905017 - Trisol System EFS Study N/A
Completed NCT02644616 - The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement Phase 4
Recruiting NCT05130775 - Measurement of Tricuspid Regurgitation Volume for Assessment of Tricuspid Regurgitation Using 3D Transesophageal Echocardiography
Active, not recruiting NCT02675244 - Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery N/A
Completed NCT01093001 - Tricuspid Regurgitation Study Phase 4
Recruiting NCT04339192 - Minimally Invasive Tricuspid Surgery vs Medical Treatment for Severe TR N/A
Completed NCT00665301 - Cardiac Output Pulmonary Arterial Catheter Compared to FloWave™ 1000 N/A
Recruiting NCT00419354 - The Impact of Right Ventricular Pacing on Tricuspid Regurgitation N/A
Not yet recruiting NCT05126030 - TRiCares Topaz Transfemoral Tricuspid Heart Valve Replacement System First In Human Trial N/A
Not yet recruiting NCT05173233 - Pivotal Study of TriStar N/A
Recruiting NCT04782908 - Hemodynamic Implications of Transcatheter Tricuspid Valve Repair in HFpEF Patients N/A
Not yet recruiting NCT04936802 - Safety and Feasibility of the Transcatheter Tricuspid Valve Repair System (Trialign) N/A